CD8A and myeloid sarcoma: Yet to be peer-reviewed, one study showed that all the MS patients on anti-CD20 therapies, and vaccinated with mRNA vaccines, generated antigen-specific CD4+ and CD8+ T-cell responses [19](pre-print), and another one, on the contrary, that such responses were detectable in 17% of patients and in 86% of healthy controls only [20](pre-print).